Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina

被引:34
作者
Gao, H
Qiao, XX
Gao, R
Mieler, WF
McPherson, AR
Holz, ER
机构
[1] Baylor Coll Med, Dept Ophthalmol, Cullen Eye Inst, Houston, TX 77030 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Shreveport, LA 71130 USA
关键词
triamcinolone; vascular endothelial growth factor; neovascularization; age-related macular degeneration;
D O I
10.1016/j.visres.2003.09.027
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Intravitreal triamcinolone inhibits choroidal neovascularization. To investigate if vascular endothelial growth factor (VEGF) is affected, we examined VEGF expression after intravitreal triamcinolone administration in rat retina. Using in situ hybridization, we have found dense clustered VEGF mRNA signals in the retinal pigment epithelium, moderate patchy signals in the inner nuclear layer, and positive labeling in a sub-population of ganglion cells. Densitometry and northern blot analysis revealed no significant alteration of VEGF mRNA expression pattern and level 3-21 days after triamcinolone injection. Our data indicate that intravitreal triamcinolone does not affect basal VEGF mRNA expression in normal adult rat retina. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:349 / 356
页数:8
相关论文
共 47 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[3]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[4]   THE EFFECTS OF INTRAVITREAL TRIAMCINOLONE ACETONIDE ON EXPERIMENTAL PRERETINAL NEOVASCULARIZATION [J].
ANTOSZYK, AN ;
GOTTLIEB, JL ;
MACHEMER, R ;
HATCHELL, DL .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1993, 231 (01) :34-40
[5]  
Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P391
[6]  
Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
[7]  
Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
[8]   Neuroimmunomodulation by macrophage migration inhibitory factor (MIF) [J].
Bucala, R .
NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES, 1998, 840 :74-82
[9]  
Campochiaro P A, 1999, Mol Vis, V5, P34
[10]   Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up [J].
Challa, JK ;
Gillies, MC ;
Penfold, PL ;
Gyory, JF ;
Hunyor, ABL ;
Billson, FA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (04) :277-281